FBRX · Forte Biosciences, Inc.

NASDAQ Capital MarketHealthcareBiotechnology

Forte Biosciences, Inc. Is A U.S.-Based Biopharmaceutical Company Currently In Its Clinical Development Phase. The Firm'S Key Initiative Involves Advancing The Fb-102 Program, Which Is Designed To Tackle A Variety Of Autoimmune Conditions, Notably Vitiligo And Alopecia Areata. Their Main Offices Are Situated In Dallas, Texas.

HealthcareNASDAQ Capital MarketUSMid Float

$38.96

+85.3% latest move

Price & move as of the most recent catalyst (Jul 9) — not a live quote.

FLOAT

16.6M

FREE FLOAT %

78%

SHARES O/S

21.2M

MARKET CAP

$1.63B

EXCHANGE

NASDAQ Capital Market

COUNTRY

FBRX Catalyst History

Regulatory and ClinicalPositive Topline ResultsJul 9, 2026 · 8:10am ET

FBRXForte Biosciences, Inc.

Forte Biosciences Reports Statistically Significant Improvement in Vitiligo with FB102

Results observed at Week 24 after completion of 12-week treatment period.

Be early on the next FBRX spark.

Day Trader Sniper alerts you the instant a setup like this triggers.

How it works Download Free →